Clinical Trials on High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) in France
Total 38 results
-
Janssen-Cilag Ltd.RecruitingMetastatic Hormone-sensitive Prostate CancerFrance, Germany, Spain, Greece, Austria, United Kingdom
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingMetastatic Hormone-sensitive Prostate CancerUnited States
-
BayerOrion Corporation, Orion PharmaCompletedMetastatic Hormone-sensitive Prostate CancerBelgium, France, Sweden, China, Canada, United States, Spain, Taiwan, Japan, Finland, Korea, Republic of, Australia, Brazil, Czechia, Israel, Italy, Netherlands, Russian Federation, Bulgaria, United Kingdom, Germany, Poland, Mexico
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.Active, not recruitingMetastatic Hormone Sensitive Prostate CancerKorea, Republic of, Japan, United States, Argentina, Australia, Belgium, Canada, Chile, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United...
-
Tavanta TherapeuticsCompletedMetastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
-
Merck Sharp & Dohme LLCActive, not recruitingMetastatic Hormone-Sensitive Prostate CancerTaiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
-
UNICANCERRecruitingOligometastatic Hormone Sensitive Prostate CancerFrance, Martinique
-
Janssen Research & Development, LLCRecruitingMetastatic Castrate-sensitive Prostate CancerUnited States, France, Mexico, Germany, Australia, Brazil, Canada, China, Poland
-
AstraZenecaRecruitingMetastatic Castration-Sensitive Prostate CancerUnited States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
-
Janssen Research & Development, LLCActive, not recruitingMetastatic Castration-sensitive Prostate CancerUnited States, Italy, China, Korea, Republic of, Canada, Australia, United Kingdom, Hungary, France, Taiwan, Thailand, Germany, Malaysia, Denmark, Russian Federation, New Zealand, Ukraine, Bulgaria, Israel, Spain, Turkey, Sweden, Cz... and more
-
AstraZenecaActive, not recruitingHormone-Sensitive Prostate CancerUnited States, Belgium, Spain, Canada, Poland, Argentina, India, Taiwan, Thailand, Vietnam, Turkey, Russian Federation, France, Germany, Korea, Republic of, Brazil, Mexico, Peru, Philippines, China, United Kingdom, Hong Kong, Israel, ... and more
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate CarcinomaUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.Active, not recruitingProstate Cancer | Cancer of the Prostate | Hormone Sensitive Prostate CancerCanada, United States, France, Spain, Australia, Sweden, Taiwan, Finland, Korea, Republic of, Netherlands, United Kingdom, Denmark, Brazil, Slovakia, Austria, Italy, Poland
-
Novartis PharmaceuticalsCompletedMetastatic Hormone Refractory Prostate CancerUnited States, France, Spain, Belgium, Singapore, Italy, Australia, Germany
-
MedImmune LLCCompletedHormone-sensitive, HER-2 Negative Metastatic Breast CancerSpain, United States, Belgium, France, United Kingdom, Canada, Israel, Germany, Hungary, Poland, Bahamas
-
Novartis PharmaceuticalsCompleted
-
MacroGenicsRecruitingProstate Cancer Recurrent | Immunotherapy | Androgen-Independent Prostatic Cancer | Androgen-Resistant Prostatic Cancer | Hormone Refractory Prostatic Cancer | Immune Checkpoint Inhibitor | Androgen-Independent Prostatic Neoplasms | Androgen-Insensitive Prostatic Cance | Inhibitory Checkpoint MoleculeUnited States, Spain, France, Belgium, United Kingdom, Poland, Georgia, Bulgaria, Puerto Rico, Australia
-
Centre Oscar LambretRecruitingOvarian Cancer | Hormone-resistant Prostate Cancer | Circulating Tumor Cell | HER2-positive Metastatic Breast CancerFrance
-
BayerCompletedBone Metastases | Hormone Refractory Prostate CancerItaly, Spain, Hong Kong, Canada, United Kingdom, France, Australia, United States, Germany, Brazil, Israel, Netherlands, Norway, Belgium, Sweden, Czech Republic, Poland, Singapore, Slovakia
-
Eli Lilly and CompanyActive, not recruitingUrogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditionsChina, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Mexico, Belgium, Korea, Republic of, Turkey, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece
-
Hospices Civils de LyonRecruitingBreast Cancer | Gastric Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cancer MetastaticFrance
-
Hospices Civils de LyonRecruitingAdult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian CancerFrance
-
AmgenCompletedBone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast CancerSpain, Czechia, Peru, Russian Federation, Austria, Lithuania, Poland, South Africa, Italy, Ukraine, Israel, Argentina, Belgium, Brazil, France, Hungary, Japan, Latvia, Panama
-
Karyopharm Therapeutics IncActive, not recruitingAcute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDSUnited States, France, Canada, Spain, China
-
Mersana TherapeuticsGOG Foundation; European Network of Gynaecological Oncological Trial Groups...TerminatedUpifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) (UP-NEXT)Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Ovarian CancerUnited States, Australia, Canada
-
PMV Pharmaceuticals, IncMerck Sharp & Dohme LLCRecruitingBreast Cancer | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Metastatic Cancer | Advanced Solid Tumor | Endometrial Cancer | Metastatic Solid Tumor | Other Cancer | Advanced Malignant Neoplasm | Locally AdvancedUnited States, Spain, Korea, Republic of, Australia, France, Germany, Italy, Singapore, United Kingdom
-
Aprea TherapeuticsCompletedPlatinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53United States, France, Spain, Netherlands, United Kingdom, Belgium, Germany, Sweden
-
AstraZenecaDaiichi SankyoRecruitingGastric Cancer | Colorectal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Biliary Tract Cancer | Metastatic Castration-resistant Prostate CancerSpain, China, Korea, Republic of, Canada, Italy, Poland, Turkey, United Kingdom, Japan, Taiwan, United States, France, Germany, Switzerland
-
MacroGenicsActive, not recruitingMelanoma | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Malignant Melanoma | Non-small Cell Carcinoma | Oral Squamous Cell Carcinoma | Small Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck | Castration-Resistant... and other conditionsSpain, Australia, United States, Korea, Republic of, France, United Kingdom, Italy, Belgium, Poland
-
WepromNot yet recruitingLeukemia, Myeloid, Acute | Metastatic Cancer | Cancer, Rectum | Myelodysplasia | Cancer, Breast | Myeloma | Leukemia, Lymphocytic, Acute | Cancer, Lung | Cancer Colon | Leukemia, Lymphocytic, Chronic | Cancer, Kidney | Cancer Pancreas | Cancer Prostate | Leukemia,Myeloid, Chronic | Cancer OvariesFrance
-
ExelixisRecruitingCervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid TumorsUnited States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
-
PfizerCompletedHepatocellular Carcinoma | Advanced Breast Cancer | Non-Small Cell Lung Cancer | Metastatic Breast Cancer | Metastatic Renal Cell Cancer | Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Gastrointestinal Stromal Tumor | Advanced Gastric Cancer | Metastatic Castration Resistant Prostate Cancer | Advanced... and other conditionsUnited States, Spain, Korea, Republic of, France, Australia, United Kingdom, Canada, Brazil, Argentina, Taiwan, Belgium, Colombia, Germany, Hong Kong, Mexico, Philippines, Singapore
-
National Cancer Institute (NCI)RecruitingStage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditionsUnited States, Puerto Rico
-
Elevation OncologyActive, not recruitingSarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bladder Cancer | Metastatic Solid Tumor | Gallbladder Cancer | Uterine Cancer | Locally Advanced Solid TumorUnited States, Korea, Republic of, Australia, Canada
-
ExelixisActive, not recruitingA Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)Renal Cell Carcinoma | Colorectal Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm MalignantUnited States, Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
National Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Acute Myeloid Leukemia | Multiple Myeloma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer... and other conditionsUnited States, Puerto Rico
-
Novartis PharmaceuticalsTerminatedMelanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
-
University of NebraskaRecruitingMelanoma | Sarcoma | Kidney Cancer | Leukemia | Breast Cancer | Laryngeal Cancer | Hypopharyngeal Cancer | Nasopharyngeal Cancer | Multiple Myeloma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Small Intestine Cancer | Ovarian Cancer | Lynch Syndrome | Lung Cancer | Rectal Cancer | Prostate Cancer | Gastrointestinal... and other conditionsUnited States